Health Care [ 3/12 ] | Biotechnology [ 26/74 ]
NASDAQ | Common Stock
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally.
The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications.
The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL " Portela & Ca,S. A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Oct 30, 24 | 1.24 Increased by +51.22% | 1.51 Decreased by -17.88% |
| Aug 1, 24 | 0.63 Decreased by -33.68% | 1.05 Decreased by -40.00% |
| May 1, 24 | 0.42 Increased by +153.16% | 1.01 Decreased by -58.42% |
| Feb 7, 24 | 1.44 Increased by +63.64% | 1.15 Increased by +25.22% |
| Oct 31, 23 | 0.82 Increased by +18.84% | 0.97 Decreased by -15.46% |
| Aug 1, 23 | 0.95 Increased by +627.78% | 0.78 Increased by +21.79% |
| May 3, 23 | -0.79 Decreased by -664.29% | 0.13 Decreased by -707.69% |
| Feb 6, 23 | 0.88 Increased by +1.20 K% | 1.16 Decreased by -24.14% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 622.10 M Increased by +24.72% | 129.80 M Increased by +56.20% | Increased by +20.86% Increased by +25.24% |
| Jun 30, 24 | 590.20 M Increased by +30.37% | 65.00 M Decreased by -31.94% | Increased by +11.01% Decreased by -47.79% |
| Mar 31, 24 | 515.30 M Increased by +22.57% | 43.40 M Increased by +156.66% | Increased by +8.42% Increased by +146.22% |
| Dec 31, 23 | 515.20 M Increased by +25.05% | 147.70 M Increased by +65.96% | Increased by +28.67% Increased by +32.71% |
| Sep 30, 23 | 498.80 M Increased by +28.59% | 83.10 M Increased by +21.31% | Increased by +16.66% Decreased by -5.66% |
| Jun 30, 23 | 452.70 M Increased by +19.70% | 95.50 M Increased by +665.09% | Increased by +21.10% Increased by +572.09% |
| Mar 31, 23 | 420.40 M Increased by +35.35% | -76.60 M Decreased by -651.08% | Decreased by -18.22% Decreased by -507.15% |
| Dec 31, 22 | 412.00 M Increased by +32.05% | 89.00 M Increased by +1.32 K% | Increased by +21.60% Increased by +1.02 K% |